Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total transaction of $76,800.00. Following the transaction, the chief financial officer now owns 19,738 shares in the company, valued at $151,587.84. The trade was a 33.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Zynex Stock Down 1.4 %

NASDAQ:ZYXI opened at $7.73 on Tuesday. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15. The company’s fifty day moving average price is $8.11 and its 200-day moving average price is $8.20. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The firm has a market capitalization of $246.20 million, a P/E ratio of 51.53 and a beta of 0.54.

Hedge Funds Weigh In On Zynex

A number of institutional investors have recently modified their holdings of the stock. Hotchkis & Wiley Capital Management LLC boosted its stake in shares of Zynex by 24.7% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 746,380 shares of the company’s stock worth $6,090,000 after buying an additional 147,770 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Zynex by 6.7% in the third quarter. Geode Capital Management LLC now owns 425,509 shares of the company’s stock valued at $3,473,000 after acquiring an additional 26,774 shares during the period. Millennium Management LLC boosted its position in Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after purchasing an additional 118,615 shares in the last quarter. Royce & Associates LP grew its stake in shares of Zynex by 9.2% during the 3rd quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock worth $2,099,000 after purchasing an additional 21,781 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in shares of Zynex by 10.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company’s stock valued at $1,276,000 after purchasing an additional 14,820 shares in the last quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ZYXI shares. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Zynex in a research report on Friday, December 6th. Royal Bank of Canada reduced their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.